SCHEMBL282364

SCHEMBL282364

O=C(Nc1ccc(O)cc1)Nc1ccc(Br)c(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
MEN1 O00255 2/20 0.59
KMT2A Q03164 2/20 0.59
NPSR1 Q6W5P4 2/20 0.59
LMNA P02545 2/20 0.59
XBP1 P17861 1/20 0.59
HTT P42858 2/20 0.57
EPHX1 P07099 2/20 0.57
NPC1 O15118 1/20 0.57
RAB9A P51151 1/20 0.57
KDR P35968 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
TMPRSS4 Q9NRS4 1/20 0.55
TRPV1 Q8NER1 4/20 0.54
RAF1 P04049 3/20 0.53
BAZ1A Q9NRL2 1/20 0.51
CA1 P00915 1/20 0.51
CA2 P00918 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29494958 0.88 MAPT (0.59) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL22103904 0.88 MAPT (0.72) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL22092704 0.88 MAPT (0.59) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL22103909 0.87 TMPRSS4 (0.64) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL29494970 0.87 MAPT (0.75) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL22092492 0.87 MAPT (0.75) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL282336 0.83 AR (0.62) KDRTRPV1BAZ1A
SCHEMBL22103803 0.82 KDR (0.70) MAPTMEN1KMT2ANPSR1LMNA
SCHEMBL281864 0.82 KDR (0.85) KDRTRPV1CA1CA2CA7
SCHEMBL22103800 0.80 MEN1 (0.62) MAPTMEN1KMT2ANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8957087-B2 Heterocyclic substituted acardite derivate and application thereof Jiangsu Provincial Institute of Materia Medica Co., Ltd. (CN) 2015-02-17 US disclosed
EP-2428506-B1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF NANJING LUYESIKE PHARMACEUTICAL CO LTD (CN) 2014-03-05 EP disclosed
EP-2428506-A1 HETEROCYCLIC SUBSTITUTED ACARDITE DERIVATES AND USE THEREOF Jiangsu Provincial Institute Of Materia Medica Co. (CN) 2012-03-14 EP disclosed
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof NANJING LUYESIKE PHARMACEUTICAL CO., LTD. (CN) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053192-A1 Heterocyclic Substituted Acardite Derivate and Application Thereof H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IDH1, CA7 MAPT 4817/4885MEN1 2063/4885KMT2A 1811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.